Triple-bead MAS: Phase III data

Top-line data from the double-blind, U.S. Phase III SHP465-306 trial in 275 ADHD patients ages 18-55 showed that once-daily 12.5 and 37.5 mg oral SHP465 each

Read the full 261 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE